Seasonal Allergic Rhinitis Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Clinical Trial Designed to Assess the Safety and Efficacy of Ciclesonide (200mcg and 100mcg, Once Daily) Applied as a Nasal Spray for Two Weeks in the Treatment of Seasonal Allergic Rhinitis (SAR) in Patients 6 to 11 Years of Age
Verified date | October 2016 |
Source | AstraZeneca |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The aim of the study is to determine the efficacy and safety of ciclesonide nasal spray in children with seasonal allergic rhinitis. Ciclesonide will be administered intranasally at two dose levels once daily. The study consists of a baseline period (1 to 3 weeks) and a treatment period (2 weeks).
Status | Completed |
Enrollment | 660 |
Est. completion date | October 2006 |
Est. primary completion date | October 2006 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 6 Years to 11 Years |
Eligibility |
Main Inclusion Criteria: - Written informed consent - General good health other than seasonal allergic rhinitis - Positive standard skin prick test Main Exclusion Criteria: - Pregnancy, nursing, or plans to become pregnant or donate gametes for in vitro fertilization - Participation in any investigational drug trial within the 30 days preceding the Screening Visit - A known hypersensitivity to any corticosteroid or any of the ingredients in the study drug formulation - Plans to travel outside the study area (the known pollen area for the investigative site) for 24 hours or more during the final 7 days of the baseline period - Plans to travel outside the study area (the known pollen area for the investigative site) for more than 2 consecutive days OR more than 3 days total during the treatment period - Use of any prohibited concomitant medications - Non-vaccinated exposure to or active infection with chickenpox or measles within the 21 days preceding the Screening Visit - Use of antiepileptic drugs for epilepsy within 30 days of the Screening Visit - Study participation by more than one patient from the same household |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Altana Pharma/Nycomed | Ashland | Oregon |
United States | Altana Pharma/Nycomed | Atlanta | Georgia |
United States | Altana Pharma/Nycomed | Austin | Texas |
United States | Altana Pharma/Nycomed | Austin | Texas |
United States | Altana Pharma/Nycomed | Bethesda | Maryland |
United States | Altana Pharma/Nycomed | Birmingham | Alabama |
United States | Altana Pharma/Nycomed | Blue Bell | Pennsylvania |
United States | Altana Pharma/Nycomed | Brick | New Jersey |
United States | Altana Pharma/Nycomed | Burke | Virginia |
United States | Altana Pharma/Nycomed | Charleston | South Carolina |
United States | Altana Pharma/Nycomed | Charleston, SC | South Carolina |
United States | Altana Pharma/Nycomed | Charlottesville | Virginia |
United States | Altana Pharma/Nycomed | Cincinnati | Ohio |
United States | Altana Pharma/Nycomed | Cincinnati, OH | Ohio |
United States | Altana Pharma/Nycomed | Colorado Springs | Colorado |
United States | Altana Pharma/Nycomed | Costa Mesa | California |
United States | Altana Pharma/Nycomed | Dallas | Texas |
United States | Altana Pharma/Nycomed | Denver | Colorado |
United States | Altana Pharma/Nycomed | Eerie | Pennsylvania |
United States | Altana Pharma/Nycomed | El Paso | Texas |
United States | Altana Pharma/Nycomed | Englewood | Colorado |
United States | Altana Pharma/Nycomed | Forked River | New Jersey |
United States | Altana Pharma/Nycomed | Gainesville | Georgia |
United States | Altana Pharma/Nycomed | Germantown | Tennessee |
United States | Altana Pharma/Nycomed | Hot Springs | Arkansas |
United States | Altana Pharma/Nycomed | Huntington Beach | California |
United States | Altana Pharma/Nycomed | Indianapolis | Indiana |
United States | Altana Pharma/Nycomed | Jackson | Tennessee |
United States | Altana Pharma/Nycomed | Jefferson City | Missouri |
United States | Altana Pharma/Nycomed | Kerrville | Texas |
United States | Altana Pharma/Nycomed | Lake Oswego | Oregon |
United States | Altana Pharma/Nycomed | Lakewood, CO | Colorado |
United States | Altana Pharma/Nycomed | Lincoln, NE | Nebraska |
United States | Altana Pharma/Nycomed | Long Beach | California |
United States | Altana Pharma/Nycomed | Los Alamitos | California |
United States | Altana Pharma/Nycomed | Louisville, KY | Kentucky |
United States | Altana Pharma/Nycomed | Medford, OR | Oregon |
United States | Altana Pharma/Nycomed | Metairie | Louisiana |
United States | Altana Pharma/Nycomed | Milwaukee | Wisconsin |
United States | Altana Pharma/Nycomed | Minneapolis | Minnesota |
United States | Altana Pharma/Nycomed | Mission Viejo | California |
United States | Altana Pharma/Nycomed | New Braunfels | Texas |
United States | Altana Pharma/Nycomed | Normal | Illinois |
United States | Altana Pharma/Nycomed | North Dartmouth | Massachusetts |
United States | Altana Pharma/Nycomed | Orange | California |
United States | Altana Pharma/Nycomed | Overland Park | Kansas |
United States | Altana Pharma/Nycomed | Papillion | Nebraska |
United States | Altana Pharma/Nycomed | Pittsburgh | Pennsylvania |
United States | Altana Pharma/Nycomed | Pittsburgh | Pennsylvania |
United States | Altana Pharma/Nycomed | Portland | Oregon |
United States | Altana Pharma/Nycomed | Raleigh | North Carolina |
United States | Altana Pharma/Nycomed | Red Bank | New Jersey |
United States | Altana Pharma/Nycomed | Richmond | Virginia |
United States | Altana Pharma/Nycomed | Rochester, NY | New York |
United States | Altana Pharma/Nycomed | Rockville Centre | New York |
United States | Altana Pharma/Nycomed | Rolla | Missouri |
United States | Altana Pharma/Nycomed | Roseville | California |
United States | Altana Pharma/Nycomed | Salt Lake City | Utah |
United States | Altana Pharma/Nycomed | San Antonio | Texas |
United States | Altana Pharma/Nycomed | San Diego | California |
United States | Altana Pharma/Nycomed | San Diego | California |
United States | Altana Pharma/Nycomed | San Jose | California |
United States | Altana Pharma/Nycomed | Savannah | Georgia |
United States | Altana Pharma/Nycomed | Shreveport | Louisiana |
United States | Altana Pharma/Nycomed | Skillman | New Jersey |
United States | Altana Pharma/Nycomed | South Burlington | Vermont |
United States | Altana Pharma/Nycomed | St. Louis | Missouri |
United States | Altana Pharma/Nycomed | Stockton | California |
United States | Altana Pharma/Nycomed | Upland | Pennsylvania |
United States | Altana Pharma/Nycomed | Warren | New Jersey |
United States | Altana Pharma/Nycomed | Woodstock, GA | Georgia |
Lead Sponsor | Collaborator |
---|---|
AstraZeneca |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Average of morning and evening parent/caregiver reported reflective total nasal symptoms score over the two weeks of treatment | |||
Secondary | Physician assessment of nasal symptoms score at endpoint | |||
Secondary | average of morning and evening parent/caregiver reported instantaneous total nasal symptom score over the two weeks of treatment | |||
Secondary | safety |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01171664 -
Clinical Trial of STAHIST in Seasonal Allergic Rhinitis (SAR) Subjects
|
Phase 2 | |
Terminated |
NCT01337323 -
Prospective Observational Study of Concomitant Allergic Rhinitis Treatment Patterns Among Patients Starting on Fluticasone Furoate Nasal Spray in a Retail Pharmacy Setting
|
N/A | |
Completed |
NCT00784732 -
A Study to Compare the Efficacy of QAV680 Against Placebo in Treating Seasonal Allergic Rhinitis in an Environmental Exposure Chamber
|
Phase 2 | |
Completed |
NCT00578929 -
Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients
|
Phase 3 | |
Completed |
NCT00619827 -
Efficacy and Safety of Sublingual Tablets of Grass Pollen Allergen Extract
|
Phase 1 | |
Completed |
NCT00209365 -
The Role of Pollen Starch Granules in Pollen Challenge Studies in the Fraunhofer Environmental Exposure Unit
|
N/A | |
Terminated |
NCT00223587 -
Seasonal Allergic Rhinitis and Driving Ability
|
Phase 4 | |
Completed |
NCT00637455 -
Single Center, Randomized, Double-Blind,Crossover Study Comparing Effects Of Single-Dose Fexofenadine HCl 180 mg, Cetirizine 10 mg, and Placebo on Cognitive Performance in Naval Flight Personnel
|
Phase 4 | |
Completed |
NCT00963599 -
Montelukast in Seasonal Allergic Rhinitis - Fall 1999 Study (0476A-117)
|
Phase 3 | |
Recruiting |
NCT05346718 -
Threshold Concentrations for Ragweed and Birch Pollen in Seasonal Allergic Rhinitis
|
N/A | |
Completed |
NCT06126952 -
Azelastine Allergen Chamber - Onset of Action Study
|
Phase 2 | |
Completed |
NCT01940146 -
Efficacy and Safety of SPARC1310 in Seasonal Allergic Rhinitis
|
Phase 2 | |
Completed |
NCT02245360 -
Study Immunology and Safety of 60-day Treatment of SQ Grass SLIT (Sublingual Immunotherapy)-Tablet in Adult Subjects With Grass Pollen-induced Allergic Rhinoconjunctivitis
|
Phase 3 | |
Completed |
NCT01230619 -
Vienna Challenge Chamber Study Using RV658 in Subjects With Allergic Rhinitis
|
Phase 2 | |
Completed |
NCT00574210 -
PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the Symptoms of SAR in an EEC Model (5-arm)
|
Phase 2 | |
Completed |
NCT00561717 -
A Randomized, Placebo Controlled Study to Determine the Efficacy and Speed of a Nasal Spray in Allergen Induced Seasonal Allergic Rhinitis
|
Phase 4 | |
Completed |
NCT00420082 -
A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge Chamber
|
Phase 2 | |
Completed |
NCT00405899 -
Pilot Study of Allergy Immunotherapy and Prevention of Viral Respiratory Infections
|
N/A | |
Completed |
NCT00443495 -
Phase I/IIa Study on Chitin Microparticles in Subjects Suffering From Allergic Rhinitis
|
Phase 1/Phase 2 | |
Completed |
NCT03097432 -
Non-interventional Study to Assess the Tolerability, the Safety Profile and the Adherence of Different Up-dosing Schemes for a Sublingual Immunotherapy Treatment
|
N/A |